Found: 1
Select item for more details and to access through your institution.
TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease ‐ Results from 12‐months.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082529
- By:
- Publication type:
- Article